ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01XX41 | B | Eribulin mesylate - 0.88mg/2ml | 9331 | 109717/1 | HALAVEN | 0.88mg/2ml | 1x2ml | Injectable solution | IV | Abela Frères S.A.L. | Eisai Manufacturing Limited | UK | 36,967,093 L.L | 19.35 | D | Eisai Europe Limited | UK | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01XX41 | B | Eribulin mesylate - 0.88mg/2ml | 9331/388 | 109717/1 | HALAVEN | 0.88mg/2ml | 1x2ml | Injectable solution | IV | Abela Frères S.A.L. | Eisai Manufacturing Limited | UK | L.L | 19.35 | D | Eisai Europe Limited | UK | 2/5/2024 |